Subscribe

JD Health International Inc. (6618.HK)

HKD37.52 +0.56 (+1.52%)
CN HKSE Healthcare Medical - Care Facilities
Address Jingdong Headquarters 101111
Beijing, CN
CEO Cao Dong
Website ir.jdhealth.com
IPO 2020-12-08
ISIN KYG5074A1004

Explore sections of this company profile

Also trades on Hong Kong Stock Exchange · 6618.HK (HKD) Other OTC · JDHIF (USD) Other OTC · JDHIY (USD)
Description

JD Health International Inc., functioning as an investment holding entity, runs an expansive digital healthcare platform across the People's Republic of China. The company supplies a diverse range of pharmaceutical and wellness products, such as over-the-counter and prescription medications, medical devices, and health supplements. These goods are distributed through both direct sales and an extensive online retail pharmacy network. Beyond product offerings, its comprehensive service suite includes virtual medical consultations, patient referrals to hospitals and doctors, health screening programs, genetic testing, and beauty care services. Additionally, it develops intelligent healthcare and wellness management solutions, alongside providing technical support and advertising services. The platform also facilitates access to various medical provisions, including general health examinations, cosmetic medical procedures, vaccination bookings, dental treatments, and nucleic acid testing. Incorporated in 2018 and headquartered in Beijing, People's Republic of China, JD Health International Inc. is a subsidiary of JD Jiankang Limited.

Market Cap & Enterprise Value
Merger & Acquisition History

No mergers or acquisitions recorded for this company.

Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary Loading…
Indicator 1D1W2W3W1M
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
Averages
Trend
Price
Levels
Draw
HKD37.52 +0.56 (+1.52%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
10M
Beta
1.13
Float Shares
1.02B
Free Float %
31.8%
Price Performance
1D5D1M3M6M YTD1Y3Y5Y10YMax
-0.26% -3.71% -15.34% -32.33% -37.15% -30.81% -4.36% -23.51% -62.83% -65.09% -65.09%
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
vs.
Loading histogram data…

Revenue flow

Revenue by geography

Revenue by segment

From To

Revenue composition

From To

By product

By geography

Financial Statements

Income Statement

Balance Sheet

Cash Flow Statement

Key Metrics

Financial Ratios

Employees

Financial Growth (CAGR)

Market Data

Price Targets & DCF
Current price
37.52
DCF (Unlevered) 5.19 -86.2%
DCF (Levered) 61.09 +62.8%

DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.

Ratings Trend (MoM) 94% Bullish
Rating 2026-05 Change
Strong Buy 3 0
Buy 14 -1
Hold 1 0
Sell 0 0
Strong Sell 0 0
Quality scores
Altman Z-Score
5.18
Safe zone
Piotroski F-Score
6 / 9
Average
MOAT Score
5 / 10
Developing
Composite Rating
A-
Overall Score
4 / 5
High
DCF Score
4 / 5
High
ROE Score
4 / 5
High
ROA Score
5 / 5
High
D/E Score
4 / 5
High
P/E Score
1 / 5
Low
P/Book Score
3 / 5
Medium
Operational MOAT
✗ Below peers
  • ✓
    Revenue growth Medical - Care Facilities: +10.2%
    +26.3% ★ Q4'25: +44.4% (vs Q4'23)
  • ✓
    EPS growth Medical - Care Facilities: +19.2%
    +27.3% ★ Q4'25: +383.3% (vs Q4'23)
  • ✓
    FCF margin FCF growth · Medical - Care Facilities: +32.0%
    +9.0% ★ Q4'25: +0.0% (vs Q4'23)
  • ✗
    EBIT margin Medical - Care Facilities: +11.3%
    +5.2% Q4'25: +4.4% (vs Q4'23)
  • ✓
    ROIC Medical - Care Facilities: +6.8%
    +24.6% ★ Q4'25: +42.7% (vs Q4'23)
  • ✗
    Share dilution Medical - Care Facilities: +0.0%
    +1.1% Q4'25: +1.2% (vs Q4'23)
  • ✓
    Debt / EBITDA Net debt/EBITDA · Medical - Care Facilities: 0.99×
    0.16× ★ Q4'25: 0.09× (vs Q4'23)
Valuation Multiples From To
Price Forecast (3Y) From To
Model
Adjust
P/E
Theoretical Return — If Invested Today

* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.

DCF Interactive Model (UFCF)
Projection years:
Market assumptions
▶ WACC components (optional)
Ke (Cost of Equity) = Rf + β (1.13) × ERP
WACC = 99% × Ke + 1% × Kd (4.1%) × (1−t)

Modifying these values recalculates WACC automatically.

Business assumptions
—
Intrinsic value (base): 5.19 Current price: 37.52
Enterprise Value: — Equity Value: — Terminal Value: — TV as % of EV: —

Base values reflect the latest available data for this company and market conditions.

Consensus Estimates
Metric Dec 2020
actual 		Dec 2021
actual 		Dec 2022
actual 		Dec 2023
actual 		Dec 2024
actual 		Dec 2025
actual 		Dec 2026
18 Rev. Ana.
12 EPS Ana. 		Dec 2027
18 Rev. Ana.
12 EPS Ana. 		Dec 2028
15 Rev. Ana.
9 EPS Ana. 		Dec 2029
11 Rev. Ana.
3 EPS Ana.
Revenue
19.38B
est: 22.25B (-12.9%)
30.68B
est: 36.49B (-15.9%)
46.74B
est: 50.33B (-7.1%)
53.53B
est: 50.94B (+5.1%)
58.16B
est: 57.77B (+0.7%)
73.44B
est: 72.02B (+2.0%)
89.88B
87.79B – 91.30B
+24.8% YoY
103.57B
96.67B – 108.24B
+15.2% YoY
117.31B
111.86B – 121.00B
+13.3% YoY
134.28B
128.04B – 138.51B
+14.5% YoY
EBITDA
-17.04B
est: -3.77B (-351.7%)
-1.37B
est: -6.19B (+77.8%)
-60.93M
est: -8.53B (+99.3%)
2.93B
est: 870.78M (+236.5%)
1.31B
est: 987.59M (+33.1%)
3.98B
est: 1.23B (+222.9%)
1.54B
1.50B – 1.56B
+24.8% YoY
1.77B
1.65B – 1.85B
+15.2% YoY
2.01B
1.91B – 2.07B
+13.3% YoY
2.30B
2.19B – 2.37B
+14.5% YoY
EBIT
-17.07B
est: -3.83B (-345.4%)
-895.49M
est: -6.29B (+85.8%)
704.91M
est: -8.67B (+108.1%)
2.70B
est: 724.63M (+273.0%)
1.16B
est: 821.83M (+41.5%)
3.80B
est: 1.02B (+270.7%)
1.28B
1.25B – 1.30B
+24.8% YoY
1.47B
1.38B – 1.54B
+15.2% YoY
1.67B
1.59B – 1.72B
+13.3% YoY
1.91B
1.82B – 1.97B
+14.5% YoY
Net Income
-17.23B
est: -11.41B (-51.0%)
-1.07B
est: -244.75M (-338.6%)
380.11M
est: 931.57M (-59.2%)
2.14B
est: 2.43B (-12.0%)
4.16B
est: 3.04B (+36.9%)
5.38B
est: 4.83B (+11.3%)
6.05B
5.26B – 6.85B
+25.4% YoY
7.57B
6.43B – 8.71B
+25.1% YoY
9.19B
7.96B – 10.42B
+21.4% YoY
10.77B
10.12B – 11.21B
+17.2% YoY
SGA
1.96B
est: 2.27B (-13.6%)
4.67B
est: 3.72B (+25.4%)
4.35B
est: 5.14B (-15.3%)
4.65B
est: 4.86B (-4.3%)
4.47B
est: 5.51B (-19.0%)
5.01B
est: 6.87B (-27.2%)
8.58B
8.38B – 8.71B
+24.8% YoY
9.89B
9.23B – 10.33B
+15.2% YoY
11.20B
10.68B – 11.55B
+13.3% YoY
12.82B
12.22B – 13.22B
+14.5% YoY
EPS
-7.80
est: -3.61 (-116.0%)
-0.35
est: -0.08 (-351.9%)
0.12
est: 0.30 (-59.5%)
0.68
est: 0.78 (-12.5%)
1.32
est: 0.96 (+37.4%)
1.70
est: 1.58 (+7.5%)
1.92
1.64 – 2.14
+21.3% YoY
2.36
2.01 – 2.73
+23.1% YoY
2.83
2.49 – 3.26
+19.7% YoY
3.37
3.17 – 3.51
+19.2% YoY
Historical Ratings (3M)
Date Rating Overall DCF ROE ROA D/E P/E P/B
2026-05-29 A- 4/5 4/5 4/5 5/5 4/5 1/5 3/5
2026-05-28 A- 4/5 4/5 4/5 5/5 4/5 1/5 3/5
2026-05-27 A- 4/5 4/5 4/5 5/5 4/5 1/5 3/5
2026-05-26 A- 4/5 4/5 4/5 5/5 4/5 1/5 3/5
2026-05-22 A- 4/5 4/5 4/5 5/5 4/5 1/5 2/5
2026-05-21 A 4/5 4/5 4/5 5/5 4/5 2/5 3/5
2026-05-20 A 4/5 4/5 4/5 5/5 4/5 2/5 3/5
2026-05-19 A 4/5 4/5 4/5 5/5 4/5 2/5 3/5
2026-05-18 A- 4/5 4/5 4/5 5/5 4/5 2/5 2/5
2026-05-15 A 4/5 4/5 4/5 5/5 4/5 2/5 3/5
2026-05-14 A 4/5 4/5 4/5 5/5 4/5 2/5 3/5
2026-05-13 A 4/5 4/5 4/5 5/5 4/5 2/5 3/5
2026-05-12 A 4/5 4/5 4/5 5/5 4/5 2/5 3/5
2026-05-11 A 4/5 4/5 4/5 5/5 4/5 2/5 3/5
2026-05-08 A- 4/5 4/5 3/5 5/5 3/5 2/5 3/5
2026-05-07 A- 4/5 4/5 3/5 5/5 3/5 2/5 3/5
2026-05-06 A- 4/5 4/5 3/5 5/5 3/5 2/5 3/5
2026-05-05 A- 4/5 4/5 3/5 5/5 3/5 2/5 3/5
2026-05-04 A- 4/5 4/5 3/5 5/5 3/5 2/5 3/5
2026-04-30 A- 4/5 4/5 3/5 5/5 3/5 2/5 3/5
2026-04-29 A- 4/5 4/5 3/5 5/5 3/5 2/5 3/5
2026-04-28 A- 4/5 4/5 3/5 5/5 3/5 2/5 3/5
2026-04-27 A- 4/5 4/5 3/5 5/5 3/5 2/5 3/5
2026-04-24 A- 4/5 4/5 3/5 5/5 3/5 2/5 3/5
2026-04-23 B+ 3/5 4/5 3/5 5/5 2/5 2/5 3/5
2026-04-22 B+ 3/5 4/5 3/5 5/5 2/5 2/5 3/5
2026-04-21 B+ 3/5 4/5 3/5 5/5 2/5 2/5 3/5
2026-04-20 B+ 3/5 4/5 3/5 5/5 2/5 2/5 3/5
2026-04-17 B+ 3/5 4/5 3/5 5/5 2/5 2/5 3/5
2026-04-16 B+ 3/5 4/5 3/5 5/5 2/5 2/5 3/5

Owner Earnings

Owner's Earnings (history) From To
Owner alignment
Owner's Earnings TTM
10.83B
OE per share TTM
3.41
Owner's Yield
8.83%
Maintenance CapEx ratio
141.98%
Maint CapEx / Avg PPE
1.0%

Ownership Overview

Ownership breakdown

Ownership breakdown not available.

At a glance
Institutional holders
—
Total invested
—
Insider transactions (90d)
0
Beneficial owners (>5%)
0
Beneficial owners (>5%)

No beneficial ownership filings recorded.

Institutional Activity (13F)

Institutional ownership trend

Institutional history not available.

Top institutional holders

Top holders not available.

ETF Ownership

Top ETFs holding this stock Held by 192 ETFs in our universe
# ETF Weight Est. AUM exposure TER
1 KraneShares CSI China Internet ETF KWEB 3.67% 191.79M 0.70%
2 KraneShares CSI China Internet UCITS ETF KWBP.L 3.66% 25.37M 0.75%
3 KraneShares CSI China Internet UCITS ETF KWEB.L 3.66% 25.41M 0.75%
4 KraneShares CSI China Internet UCITS ETF KWBE.L 3.66% 25.33M 0.75%
5 KraneShares FTSE Emerging Markets Consumer Technology Index ETF KEMQ 2.30% 629.4K 0.80%
6 Kodex China Hang Seng Tech 372330.KS 1.71% 1.54M 0.12%
7 Pacer Emerging Markets Cash Cows 100 ETF ECOW 1.50% 3.20M 0.70%
8 KraneShares Hang Seng TECH Index ETF KTEC 1.27% 720.8K 0.69%
9 Amundi MSCI China Tech UCITS ETF USD CC1U.L 1.24% 3.63M 0.55%
10 Amundi MSCI China Tech UCITS ETF EUR CC1.PA 1.24% 3.63M 0.55%

Insider Activity

Insider Activity — Latest Quarter

No insider activity available.

Insider buys vs sells (history)

Insider history not available.

Recent insider transactions

No recent insider transactions.

Executive team

Top executives
EBIT / Employee
1.07M
Shares Outstanding
3.21B

Executive compensation

Executive compensation (annual)

Executive compensation not available.

CEO compensation breakdown

No CEO compensation history available.

Proxy statements

Proxy statements (DEF 14A)

No proxy statements available for this company yet.

Recent SEC filings

Recent SEC filings

No SEC filings available for this company yet.

Executive team

NameTitleCompensationGender
Cao Dong Chief Executive Officer & Director 988.1K male
Deng Hui Chief Financial Officer — female
Ming King Chiu FCIS Company Secretary — male
ESG Score History

No data available for this company.

Senate Trading Activity

No Senate trading activity found for this company.

House Trading Activity

No House trading activity found for this company.

Market share among peers
Peer comparison — filtered group (TTM)
Your opinion

Share your view on this stock and instantly see how the community has voted over the last 6 months.

These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.

Dividend history

Earnings history

Earnings reports

Stock splits

Related companies

Largest companies in Medical - Care Facilities